Catalog No.
YVV00502
Expression system
E. coli
Species
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Protein length
Glu819-Asn919
Predicted molecular weight
13.14 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P0DTC2
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
S2 Protein, Spike protein S2, Spike protein S2', Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, S
The furin cleavage site is required for pathogenesis, but not transmission, of SARS-CoV-2., PMID:40492735
Unveiling the structural spectrum of SARS-CoV-2 fusion by in situ cryo-ET., PMID:40461447
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base., PMID:40447603
Allostery Links hACE2 Binding, Pan-variant Neutralization and Helical Extension in the SARS-CoV-2 Spike Protein., PMID:40447075
Influence of Steric and Electronic Properties of P2 Groups on Covalent Inhibitor Binding to SARS-CoV-2 Main Protease., PMID:40437897
Identification of broad-spectrum Mpro inhibitors: a focus on high-risk coronaviruses and conserved interactions., PMID:40396609
Optimizing the pharmacokinetics and selectivity of TMPRSS2 inhibitors., PMID:40382841
LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants., PMID:40375579
The Binding of Brazilin from C. sappan to the Full-Length SARS-CoV-2 Spike Proteins., PMID:40362339
mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 variant in the lower and upper respiratory tract., PMID:40342969
Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry., PMID:40285013
Self-assembled epitope-based nanoparticles targeting the SARS-CoV-2 spike protein enhanced the immune response and induced potential broad neutralizing activity., PMID:40270771
Deep Learning-Based Comparative Prediction and Functional Analysis of Intrinsically Disordered Regions in SARS-CoV-2., PMID:40244295
Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses., PMID:40226608
Silaproline-bearing nirmatrelvir derivatives are potent inhibitors of the SARS-CoV-2 main protease highlighting the value of silicon-derivatives in structure-activity-relationship studies., PMID:40220677
Structural basis and mode of action for two broadly neutralizing nanobodies targeting the highly conserved spike stem-helix of sarbecoviruses including SARS-CoV-2 and its variants., PMID:40215243
Proteomic Analysis of 442 Clinical Plasma Samples From Individuals With Symptom Records Revealed Subtypes of Convalescent Patients Who Had COVID-19., PMID:40207927
Capture of fusion-intermediate conformations of SARS-CoV-2 spike requires receptor binding and cleavage at either the S1/S2 or S2' site., PMID:40198676
Accelerating the Hit-To-Lead Optimization of a SARS-CoV-2 Mpro Inhibitor Series by Combining High-Throughput Medicinal Chemistry and Computational Simulations., PMID:40186586
Cleaved vs. Uncleaved: How Furin Cleavage Reshapes the Conformational Landscape of SARS-CoV-2 Spike., PMID:40161653
Membrane-targeted immunogenic compositions using exosome mimetic approach for vaccine development against SARS-CoV-2 and other pathogens., PMID:40157987
Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma., PMID:40133428
Alveolar epithelial type 2 cell specific loss of IGFBP2 activates inflammation in COVID-19., PMID:40121473
The fusion peptide of the spike protein S2 domain may be a mimetic analog of β-coronaviruses and serve as a novel virus-host membrane fusion inhibitor., PMID:40101846
Determinants and dynamics of the seroprevalence of anti-SARS-CoV-2 antibodies in Poland., PMID:40097104
SARS CoV-2 spike adopts distinct conformational ensembles in situ., PMID:40093071
Expanding the utilization of binding pockets proves to be effective for noncovalent small molecule inhibitors against SARS-CoV-2 Mpro., PMID:40090296
Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine., PMID:40088511
Unveiling the Complete Spectrum of SARS-CoV-2 Fusion Stages by In Situ Cryo-ET., PMID:40060467
Structural and Conformational Impact of Deleterious Spike Protein Mutations in SARS-CoV-2 Omicron Lineages., PMID:40060440
A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants., PMID:40000611
NIEAs elicited by wild-type SARS-CoV-2 primary infection fail to enhance the infectivity of Omicron variants., PMID:39994733
Transmembrane protease serine 2 (TMPRSS2) inhibitors screened from an Fv-antibody library for preventing SARS-CoV-2 infection., PMID:39990164
High rate of RNAemia and impaired immunity in patients with immunodeficiency in the vaccination era., PMID:39985863
The Interplay of Furin Cleavage and D614G in Modulating SARS-CoV-2 Spike Protein Dynamics., PMID:39975226
Concordance of maternal and cord blood SARS-COV-2 immunoglobulin seropositivity after COVID-19 infection or vaccination in pregnancy., PMID:39973524
Epitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold., PMID:39966941
A shark-derived broadly neutralizing nanobody targeting a highly conserved epitope on the S2 domain of sarbecoviruses., PMID:39955548
Recombinant protein HR212 targeting heptad repeat 2 domain in spike protein S2 subunit elicits broad-spectrum neutralizing antibodies against SARS-CoV-2 and its variants., PMID:39931737
A novel method for detecting SARS-CoV-2 IgM and IgG based on the gold immune chromatography assay., PMID:39929938
One-pot synthesis of multifunctional sliver nanoparticles with controlled size for sensitive colorimetric and electrochemiluminescent immunoassay of SARS-CoV-2., PMID:39919859
Structural prediction of chimeric immunogen candidates to elicit targeted antibodies against betacoronaviruses., PMID:39908344
Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target., PMID:39889696
Characterization of spike S1/S2 processing and entry pathways of lentiviral pseudoviruses bearing seasonal human coronaviruses NL63, 229E, and HKU1 spikes., PMID:39873512
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques., PMID:39847599
Reverse mutational scanning of SARS-CoV-2 spike BA.2.86 identifies epitopes contributing to immune escape from polyclonal sera., PMID:39827186
Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice., PMID:39774966
Characterization of Site-Specific N- and O-Glycopeptides from Recombinant Spike and ACE2 Glycoproteins Using LC-MS/MS Analysis., PMID:39769415
The identification of a SARs-CoV2 S2 protein derived peptide with super-antigen-like stimulatory properties on T-cells., PMID:39762551
Integrated in Silico and in Vitro Studies of Rutin's Potential against SARS-CoV-2 through the Inhibition of the RNA-dependent RNA Polymerase., PMID:39757685
For research use only. Not for human or drug use.
